Spots Global Cancer Trial Database for proleukin
Every month we try and update this database with for proleukin cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| High-Dose Interleukin-2 (HDIL-2), Combined With recMAGE-A3 + AS15 ASCI | NCT01266603 | Melanoma | HDIL-2 recMAGE-A3 + AS... | 18 Years - | M.D. Anderson Cancer Center | |
| Haploidentical Natural Killer (NK) Cells With Epratuzumab for Relapsed Acute Lymphoblastic Leukemia (ALL) | NCT00941928 | Leukemia Pediatric Cance... | Epratuzumab Fludarabine Cyclophosphamid... Mesna Infusion of NK ... Interleukin-2 | - | M.D. Anderson Cancer Center | |
| Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer | NCT05267626 | Advanced Solid ... Metastatic Canc... | AU-007 Aldesleukin | 18 Years - | Aulos Bioscience, Inc. | |
| Systemic Therapy With Interferon, Interleukin-2 and BRAF Inhibitor | NCT01603212 | Melanoma | Vemurafenib IL-2 Interferon Alph... | 18 Years - 65 Years | M.D. Anderson Cancer Center | |
| CD19-specific T Cell Infusion in Patients With B-Lineage Lymphoid Malignancies | NCT00968760 | Lymphoma B-cell Lymphoma | Leukapheresis Stem Cell Trans... CD19-specific T... IL-2 Carmustine Etoposide Cytarabine Melphalan | 18 Years - 75 Years | M.D. Anderson Cancer Center | |
| IPI-Biotherapy for Patients Previously Treated With Cytotoxic Drugs With Metastatic Melanoma | NCT01409187 | Melanoma | Ipilimumab Interferon Interleukin-2 (... | 18 Years - 65 Years | M.D. Anderson Cancer Center | |
| Haploidentical Natural Killer (NK) Cells in Patients With Relapsed or Refractory Neuroblastoma | NCT00698009 | Neuroblastoma | Fludarabine Cyclophosphamid... Natural Killer ... Mesna Interleukin-2 | - | M.D. Anderson Cancer Center | |
| To Evaluate the Safety and Efficacy of ADP-TILIL7 in Patients With Locally Advanced or Metastatic Melanoma | NCT06204991 | Melanoma Stage ... Melanoma Stage ... Melanoma | ADP-TILIL7 Cyclophosphamid... Fludarabine Pho... Proleukin | 18 Years - 75 Years | Herlev Hospital | |
| Adoptive Cell Therapy Across Cancer Diagnoses | NCT03296137 | Cancer | Autologous tumo... Ipilimumab Nivolumab proleukin Cyclophosphamid... Fludara | 18 Years - 70 Years | Herlev Hospital | |
| High-Dose Interleukin-2 (HDIL-2), Combined With recMAGE-A3 + AS15 ASCI | NCT01266603 | Melanoma | HDIL-2 recMAGE-A3 + AS... | 18 Years - | M.D. Anderson Cancer Center | |
| Alloreactive NK Cells for Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) | NCT00402558 | Myelodysplastic... Leukemia | Thymoglobulin Busulfan Fludarabine Alloreactive NK... G-CSF Tacrolimus Methotrexate Interleukin-2 | - 70 Years | M.D. Anderson Cancer Center | |
| Adoptive Cell Therapy Across Cancer Diagnoses | NCT03296137 | Cancer | Autologous tumo... Ipilimumab Nivolumab proleukin Cyclophosphamid... Fludara | 18 Years - 70 Years | Herlev Hospital | |
| Cisplatin, Temozolomide, Abraxane, With Interleukin-2 and Interferon for Metastatic Melanoma | NCT00970996 | Melanoma | Temozolomide Abraxane Cisplatin Interleukin-2 Interferon alph... | 18 Years - 65 Years | M.D. Anderson Cancer Center | |
| A Phase 2, Single-Center, Open Label Study of Autologous, Adoptive Cell Therapy Following a Reduced Intensity, Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Urothelial Carcinoma Patients | NCT04383067 | Metastatic Urot... | Tumor Infiltrat... Proleukin | 18 Years - | Sheba Medical Center | |
| Biochemotherapy With Temozolomide for Metastatic Melanoma | NCT00505635 | Melanoma | Temozolomide Velban Cisplatin Interleukin-2 Intron-A Thalidomide | 18 Years - 65 Years | M.D. Anderson Cancer Center | |
| IPI-Biotherapy for Patients Previously Treated With Cytotoxic Drugs With Metastatic Melanoma | NCT01409187 | Melanoma | Ipilimumab Interferon Interleukin-2 (... | 18 Years - 65 Years | M.D. Anderson Cancer Center | |
| A Phase 2, Single-Center, Open Label Study of Autologous, Adoptive Cell Therapy Following a Reduced Intensity, Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Urothelial Carcinoma Patients | NCT04383067 | Metastatic Urot... | Tumor Infiltrat... Proleukin | 18 Years - | Sheba Medical Center | |
| Alloreactive NK Cells for Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) | NCT00402558 | Myelodysplastic... Leukemia | Thymoglobulin Busulfan Fludarabine Alloreactive NK... G-CSF Tacrolimus Methotrexate Interleukin-2 | - 70 Years | M.D. Anderson Cancer Center | |
| Treating Patients With Childhood Acute Myeloid Leukemia With Interleukin-2 | NCT00149162 | Leukemia | proleukin | - 18 Years | Assistance Publique - Hôpitaux de Paris | |
| Biochemotherapy With Temozolomide for Metastatic Melanoma | NCT00505635 | Melanoma | Temozolomide Velban Cisplatin Interleukin-2 Intron-A Thalidomide | 18 Years - 65 Years | M.D. Anderson Cancer Center | |
| A Phase 2, Single-Center, Open Label Study of Autologous, Adoptive Cell Therapy Following a Reduced Intensity, Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Urothelial Carcinoma Patients | NCT04383067 | Metastatic Urot... | Tumor Infiltrat... Proleukin | 18 Years - | Sheba Medical Center | |
| Lymphodepletion Plus Adoptive Cell Transfer With or Without Dendritic Cell Immunization in Patients With Metastatic Melanoma | NCT00338377 | Melanoma | Dendritic Cell ... Cyclophosphamid... Fludarabine T-Cells Interleukin-2 Mesna Intrathecal T-C... Intrathecal Int... | 12 Years - | M.D. Anderson Cancer Center | |
| Cisplatin, Temozolomide, Abraxane, With Interleukin-2 and Interferon for Metastatic Melanoma | NCT00970996 | Melanoma | Temozolomide Abraxane Cisplatin Interleukin-2 Interferon alph... | 18 Years - 65 Years | M.D. Anderson Cancer Center | |
| IPI Biochemotherapy for Chemonaive Patients With Metastatic Melanoma | NCT01409174 | Melanoma | Ipilimumab Temozolomide Cisplatin Interferon Alfa... Interleukin-2 | 18 Years - 65 Years | M.D. Anderson Cancer Center | |
| Adjuvant, Combined Interleukin 2 (Proleukin) and DTIC (Dacarbazine) in High-risk Melanoma Patients | NCT00553618 | Metastatic Mela... | Proleukin and D... | 18 Years - | University of Louisville |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
